Emulate Stock

emulatebio.comBioTechFounded: 2014Funding to Date: $202.31MM

Emulate is a biotechnology company developing advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Emulate, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

David Coon
Chief Executive Officer
Geraldine Hamilton Ph.D
Chief Scientific Officer & President
Harry Dhaliwal
Chief Financial Officer
Lewis Rowe
Chief Strategist
Donald Ingber Ph.D
Scientific Founder & Chair of the Scientific Advisory Board
Daniel Levner Ph.D
Co-Founder & Chief Technology Officer

Board Members

Aaron VanDevender Ph.D
Founders Fund
Donald Ingber Ph.D
Eric Moessinger
Frank Witney Ph.D
Sharon Kedar
Shlomo Melmed

Other companies like Emulate in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Emulate’s plan is to invest more heavily in R&D, and create specific organ-on-a-chip applications that they’ve homed in on through conversations with drug companies. So far, Emulate counts 21 major drug companies, including Genentech andJohnson & Johnson as customers.
Emulate has secured a $36 million Series C financing round led by Founders Fund for commercialization of the Human Emulation System™.
Emulate, which creates living products for understanding how diseases, medicines, chemicals, and foods affect human health, raised $36m